Biodexa Pharmaceuticals Completes $3M Final Match Payment To Access Remaining $17M CPRIT Grant For Phase 3 Study Of ERapa In Familial Adenomatous Polyposis, CEO Highlights Strategic Milestone
Biodexa Pharmaceuticals Completes $3M Final Match Payment To Access Remaining $17M CPRIT Grant For Phase 3 Study Of ERapa In Familial Adenomatous Polyposis, CEO Highlights Strategic Milestone
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.